Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for TaiGen Biopharmaceuticals Holdings's Return-on-Tangible-Equity or its related term are showing as below:
ROCO:4157'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -67.86 Med: -12.6 Max: 94.29
Current: 4.52
During the past 13 years, TaiGen Biopharmaceuticals Holdings's highest Return-on-Tangible-Equity was 94.29%. The lowest was -67.86%. And the median was -12.60%.
ROCO:4157's Return-on-Tangible-Equity is ranked better than 81.42% of 1200
companies
in the Biotechnology industry
Industry Median: -42.305
vs ROCO:4157: 4.52
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
TaiGen Biopharmaceuticals Holdings Return-on-Tangible-Equity Related Terms
TaiGen Biopharmaceuticals Holdings Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4157 vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, TaiGen Biopharmaceuticals Holdings's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TaiGen Biopharmaceuticals Holdings Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TaiGen Biopharmaceuticals Holdings's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where TaiGen Biopharmaceuticals Holdings's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 84.76% mean?
TaiGen Biopharmaceuticals Holdings (ROCO:4157) has a Return-on-Tangible-Equity of 84.76% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on TaiGen Biopharmaceuticals Holdings and its competitors. According to the industry distribution chart, TaiGen Biopharmaceuticals Holdings ranks #223 out of 1200 companies in the Biotechnology industry, placing it in the top 18.6%.
Is TaiGen Biopharmaceuticals Holdings' Return-on-Tangible-Equity too high?
TaiGen Biopharmaceuticals Holdings' current Return-on-Tangible-Equity is 84.76%. Based on the distribution chart, TaiGen Biopharmaceuticals Holdings ranks #223 out of 1200 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, TaiGen Biopharmaceuticals Holdings has a GF Score™ of 59/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiGen Biopharmaceuticals Holdings' Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TaiGen Biopharmaceuticals Holdings ranks #223 out of 1200 companies for Return-on-Tangible-Equity. This places TaiGen Biopharmaceuticals Holdings in the top 19% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on TaiGen Biopharmaceuticals Holdings and its competitors. TaiGen Biopharmaceuticals Holdings's current Return-on-Tangible-Equity is 84.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiGen Biopharmaceuticals Holdings stock overvalued right now?
Based on GuruFocus' analysis, TaiGen Biopharmaceuticals Holdings (ROCO:4157) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$34.27, compared to a current price of NT$8.48 — trading 75.3% below its estimated fair value. The current Return-on-Tangible-Equity is 84.76%. TaiGen Biopharmaceuticals Holdings' overall GF Score™ is 59/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For TaiGen Biopharmaceuticals Holdings (ROCO:4157), the current Return-on-Tangible-Equity is 84.76% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TaiGen Biopharmaceuticals Holdings (ROCO:4157) Overvalued in 2026?
Based on GuruFocus' analysis, TaiGen Biopharmaceuticals Holdings stock appears to be undervalued.
The current stock price of NT$8.48 is trading 75.3% below its estimated GF Value™ of NT$34.27.
GuruFocus considers TaiGen Biopharmaceuticals Holdings to be Significantly Undervalued.
Key valuation signals for ROCO:4157:
Return-on-Tangible-Equity: 84.76%
GF Value™: NT$34.27 vs. price of NT$8.48 (75.3% below fair value)
No single metric tells the full story. See the ROCO:4157 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TaiGen Biopharmaceuticals Holdings Business Description
TaiGen Biopharmaceuticals Holdings Ltd is mainly engaged in the research and development of new drugs, including the selection of drug candidates, pre-IND trials and clinical trials. Its operating segment includes development, research and sales of new drugs, and other. The majority of the revenue is generated from development, research and sales of new drugs.
59GF Score
Get the complete analysis for ROCO:4157
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4157 has been successfully added to your 
